Sign Out
Use in Pregnancy: There are no adequate and well-controlled studies of Tykerb in pregnant women. The effect of Tykerb on human pregnancy is unknown. Tykerb should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus. Women of childbearing potential should be advised to use adequate contraception and avoid becoming pregnant while receiving treatment with Tykerb.
Tykerb was not teratogenic when studied in pregnant rats and rabbits but caused minor abnormalities at doses which were maternally toxic (see Toxicology under Pharmacology under Actions).
Use in Lactation: It is not known whether lapatinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for adverse reactions in breastfeeding infants from lapatinib, it is recommended that breastfeeding be discontinued in women who are receiving therapy with Tykerb.
